Webinar information
Webinar Access Required
Please fill out the form below to access this past webinar.
Fill the form to watch the webinarIf you are having trouble viewing the webinar video, please try clearing your browser’s cookies/cache.
How can we improve diagnostic yield for patients with complex phenotypes? During our Satellite Session at ESHG 2021, Executive Medical Director Tero-Pekka Alastalo, MD, PhD, discussed the benefits of combining high-quality mtDNA analysis with routine panel-based diagnostics.
During the talk, Dr Alastalo presented Blueprint Genetics approach to improving diagnostic yield with:
- High-resolution copy number variant detection
- Inclusion of noncoding variants
- Resolving clinically important difficult-to-sequence regions
- High-quality mitochondrial DNA analysis
Watch a recording of our other ESHG 2021 presentation on solving diagnostic challenges in difficult-to-sequence regions with a special focus on hearing loss, led by Senior Manager of Genomic Services Kim Gall, MSc, CGC.
Speakers
Tero-Pekka Alastalo
Tero-Pekka is the Executive Director of Medical, and also a co-founder at Blueprint Genetics. He is based in San Francisco and holds various responsibilities in the North American operations of the company. Tero-Pekka has an MD-PhD degree and is specialized in pediatrics and pediatric cardiology. He has a PhD in molecular and cellular biology as well. During his 3-year postdoctoral training at Stanford University School of Medicine, he focused on the molecular genetic mechanisms of cardiovascular disease.